AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7633476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Ho/Nd:YAG laser ablation
Number of subjects: 142
Study 7633476 — intervention group
Group type: COMPARATOR
Intervention: Holmium-only technique
Number of subjects: 142
Study 2577711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem continuation (Group D)
Number of subjects: 31
Study 2577711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem withdrawal (Group DW)
Number of subjects: 31
Study 2577711 — intervention group
Group type: COMPARATOR
Intervention: Reference group (Group R)
Number of subjects: 31
Study 2577711 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma diltiazem concentrations during CPB
Number of subjects: 31
Study 74457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 0
Study 74457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31201188 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks treatment with oral doxycycline
Number of subjects: 120
Study 31201188 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks treatment with oral doxycycline
Number of subjects: 120
Study 27507903 — intervention group
Group type: EXPERIMENTAL
Intervention: FUSE colonoscopy
Number of subjects: 658
Study 27507903 — intervention group
Group type: COMPARATOR
Intervention: SFV colonoscopy
Number of subjects: 658
Study 26401598 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology massage (pressure on the right foot for 10 minutes and Shen Men point of the ear for 1 minute)
Number of subjects: 105
Study 26401598 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 105
Study 26401598 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (pressure on the left foot and left earlobe)
Number of subjects: 105
Study 26401598 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology group
Number of subjects: 105
Study 24237937 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 hours of training at the workplace
Number of subjects: 14
Study 24237937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 20220046 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated glucose-insulin model
Number of subjects: 59
Study 20220046 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian variations in glucose homeostasis
Number of subjects: 59
Study 19722790 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐SRP
Number of subjects: 30
Study 19722790 — intervention group
Group type: EXPERIMENTAL
Intervention: PM‐SRP
Number of subjects: 30
Study 19722790 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 17596109 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.42/6 : 1
Number of subjects: 0
Study 17596109 — intervention group
Group type: COMPARATOR
Intervention: HES 130/0.4/9 : 1
Number of subjects: 0
Study 17596109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentastarch (HES 200/0.5/5:1)
Number of subjects: 0
Study 15238020 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of the perpetrator's description before identification
Number of subjects: 0
Study 15238020 — intervention group
Group type: COMPARATOR
Intervention: Forced-choice procedure without verbalization
Number of subjects: 0
Study 15238020 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of verbalization effects
Number of subjects: 0
Study 11327626 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h sodium excretion in postmenopausal women
Number of subjects: 2212
Study 11327626 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h sodium excretion in premenopausal women
Number of subjects: 2212
Study 11327626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-center correlation analyses of 24h sodium excretion
Number of subjects: 2212
Study 9594209 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilutional HDF
Number of subjects: 40
Study 9594209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilutional HDF
Number of subjects: 40
Study 9594209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 40
Study 9594209 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate HD
Number of subjects: 40
Study 9594209 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilutional HF
Number of subjects: 40
Study 8934963 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.375 or 0.50 mg)
Number of subjects: 31
Study 8934963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3355641 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic reconstruction
Number of subjects: 20
Study 3355641 — intervention group
Group type: COMPARATOR
Intervention: Miniarthrotomy reconstruction
Number of subjects: 20
Study 31161583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal medicine residents and attending physicians
Number of subjects: 67
Study 31161583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal medicine residents
Number of subjects: 67
Study 30691749 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation (M)
Number of subjects: 40
Study 30691749 — intervention group
Group type: COMPARATOR
Intervention: Stabilization exercises (S)
Number of subjects: 40
Study 29096775 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐InTERACT (10 to 14 sessions addressing parenting skills, TBI education, stress, and anger management)
Number of subjects: 113
Study 29096775 — intervention group
Group type: EXPERIMENTAL
Intervention: Express (7 online parent skills sessions)
Number of subjects: 113
Study 29096775 — intervention group
Group type: COMPARATOR
Intervention: IRC (access to online TBI and parent skills resources)
Number of subjects: 113
Study 25465108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg per day) for 7 days, started within 48 h of stroke onset
Number of subjects: 4011
Study 25465108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue antihypertensive drugs
Number of subjects: 4011
Study 25465108 — intervention group
Group type: COMPARATOR
Intervention: No glyceryl trinitrate (control group)
Number of subjects: 4011
Study 25465108 — intervention group
Group type: COMPARATOR
Intervention: Stop antihypertensive drugs
Number of subjects: 4011
Study 25465108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 4011
Study 23245443 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) in STICH patients (SSVR)
Number of subjects: 21
Study 23245443 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) in non-STICH patients (NSSVR)
Number of subjects: 21
Study 21597880 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training program
Number of subjects: 32
Study 21597880 — intervention group
Group type: COMPARATOR
Intervention: Visual perception training
Number of subjects: 32
Study 18165592 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus ketamine (1.5 mg each) - Group MK
Number of subjects: 352
Study 18165592 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (1.5 mg) - Group M
Number of subjects: 352
Study 17314337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen of salmeterol (50 microg) plus fluticasone propionate (500 microg) twice daily
Number of subjects: 6112
Study 17314337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112
Study 17314337 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 6112
Study 17314337 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate alone
Number of subjects: 6112
Study 17314337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen of salmeterol plus fluticasone
Number of subjects: 6112
Study 17314337 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (in combination or alone)
Number of subjects: 6112
Study 15119869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdenture
Number of subjects: 60
Study 15119869 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 60
Study 11731731 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst-suppression anesthesia (BSA)
Number of subjects: 20
Study 11731731 — intervention group
Group type: COMPARATOR
Intervention: Sham-burst-suppression anesthesia (sham-BSA)
Number of subjects: 20
Study 9457400 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous rIL-2 (720,000 IU/kg)
Number of subjects: 348
Study 9457400 — intervention group
Group type: COMPARATOR
Intervention: Low-dose intravenous rIL-2 (72,000 IU/kg)
Number of subjects: 348
Study 9457400 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous outpatient rIL-2 (week 1: 250,000 IU/kg/day for 5 of 7 days; weeks 2-6: 125,000 IU/kg/day for 5 of 7 days)
Number of subjects: 348
Study 8032699 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT3 receptor antagonist (5‐HT3 RA)
Number of subjects: 0
Study 8032699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 0
Study 8032699 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 0
Study 3583492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulglycotide (400 mg thrice daily)
Number of subjects: 16
Study 3583492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31003653 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised breathing exercise regimen
Number of subjects: 51
Study 31003653 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised breathing exercise regimen
Number of subjects: 51
Study 31003653 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 28666096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 65
Study 28666096 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg)
Number of subjects: 65
Study 28666096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 65
Study 26596730 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg twice daily for 1 month)
Number of subjects: 30
Study 26596730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin B complex tablets)
Number of subjects: 30
Study 26596730 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 30
Study 26596730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25411735 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer of collagen membrane (test)
Number of subjects: 36
Study 25411735 — intervention group
Group type: COMPARATOR
Intervention: Flowable polylactide polymer (control)
Number of subjects: 36
Study 21960180 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot naltrexone (XRNT)
Number of subjects: 15
Study 19930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg
Number of subjects: 1165
Study 19930332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study 17342558 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus intraoperative intercostals neural blockade using 0.5% bupivacaine‐adrenaline
Number of subjects: 61
Study 17342558 — intervention group
Group type: COMPARATOR
Intervention: Only general anesthesia (control group)
Number of subjects: 61
Study 15313081 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based intervention
Number of subjects: 200
Study 15313081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-based intervention
Number of subjects: 200
Study 15313081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 200
Study 15313081 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 11468201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (180-microgram/kg bolus followed by 2 microgram/kg per minute infusion) with a second bolus of 90 microgram/kg
Number of subjects: 39
Study 11468201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (250-microgram/kg bolus followed by 3 microgram/kg per minute infusion) with a second bolus of 125 microgram/kg
Number of subjects: 39
Study 11468201 — intervention group
Group type: COMPARATOR
Intervention: Single-bolus regimens of eptifibatide
Number of subjects: 39
Study 11468201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9684070 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in normal eyes
Number of subjects: 20
Study 9684070 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in eyes with corneal abnormalities
Number of subjects: 20
Study 9684070 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in patients with high irregular astigmatism
Number of subjects: 20
Study 8067786 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU/m2/day of recombinant human growth hormone (rhGH)
Number of subjects: 38
Study 8067786 — intervention group
Group type: COMPARATOR
Intervention: 2 IU/m2/day of recombinant human growth hormone (rhGH)
Number of subjects: 38
Study 8067786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of rhGH
Number of subjects: 38
Study 8067786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of rhGH treatment
Number of subjects: 38
Study 8067786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of rhGH treatment
Number of subjects: 38
Study 3065157 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC three tablets at bedtime (81 mmol)
Number of subjects: 251
Study 3065157 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC three tablets in the morning plus three tablets at bedtime (bd) (162 mmol)
Number of subjects: 251
Study 3065157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 251
Study 3065157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 31834058 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 31834058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 29879711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated water (0.70 mg F/L)
Number of subjects: 12
Study 29879711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated salt (183.7 mg F/kg)
Number of subjects: 12
Study 29879711 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated water and salt (control group)
Number of subjects: 12
Study 28426301 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLA en Grupos intervention
Number of subjects: 304
Study 25810468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Number of subjects: 0
Study 25810468 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 0
Study 24589049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated evidence-based practice (EBP) study on urinary catheterization
Number of subjects: 0
Study 21838411 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 528
Study 21838411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 19289619 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus trastuzumab (6 mg/kg body weight in 3-week cycles)
Number of subjects: 156
Study 19289619 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (2,500 mg/m2 on days 1 through 14)
Number of subjects: 156
Study 19289619 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus trastuzumab
Number of subjects: 156
Study 19289619 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 156
Study 17546382 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior dentist group
Number of subjects: 164
Study 17546382 — intervention group
Group type: COMPARATOR
Intervention: Senior dentist group
Number of subjects: 164
Study 15326069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD with TDI of >=469 ms
Number of subjects: 102
Study 15326069 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICD with TDI 30 to 60 ms above the slowest documented VT cycle length
Number of subjects: 102
Study 11092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day, n = 8)
Number of subjects: 32
Study 11092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg/day, n = 8)
Number of subjects: 32
Study 11092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg/day, n = 8)
Number of subjects: 32
Study 11092994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study 9350384 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 417
Study 9350384 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 417
Study 9350384 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 2.5 mg
Number of subjects: 417
Study 9350384 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 417
Study 9350384 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg and 10 mg
Number of subjects: 417
Study 8421262 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management programme (SM)
Number of subjects: 27
Study 8421262 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management programme including relaxation training (SM + R)
Number of subjects: 27
Study 8421262 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - pharmacological treatment only
Number of subjects: 27
Study 3533547 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 34
Study 3533547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3533547 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (after withdrawal)
Number of subjects: 34
Study 3533547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after withdrawal)
Number of subjects: 34
Study 29871371 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpedicular approach (SP)
Number of subjects: 50
Study 29871371 — intervention group
Group type: COMPARATOR
Intervention: Retrodiscal approach (RD)
Number of subjects: 50
Study 29871371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SP and RD groups
Number of subjects: 50
Study 27173037 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA sirolimus-eluting stent (SES)
Number of subjects: 2348
Study 27173037 — intervention group
Group type: COMPARATOR
Intervention: Excel sirolimus-eluting stent (SES)
Number of subjects: 2348
Study 25047927 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional positioning technique during maxillary repositioning along with an intermediate occlusal splint
Number of subjects: 26
Study 25047927 — intervention group
Group type: COMPARATOR
Intervention: Intermediate occlusal splint with internal reference points
Number of subjects: 26
Study 22517228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived collagen (BDC)/ionic silver dressing
Number of subjects: 10
Study 22517228 — intervention group
Group type: COMPARATOR
Intervention: Sodium carboxymethylcellulose/1.2% ionic silver (CMC) dressing
Number of subjects: 10
Study 21284249 — intervention group
Group type: EXPERIMENTAL
Intervention: New Pro‐Argin formula toothpaste (8.0% arginine, 1450 ppm fluoride)
Number of subjects: 121
Study 21284249 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial Pro‐Argin formula toothpaste (8.0% arginine, 1450 ppm fluoride)
Number of subjects: 121
Study 21284249 — intervention group
Group type: COMPARATOR
Intervention: Negative control toothpaste (calcium carbonate, 1450 ppm fluoride)
Number of subjects: 121
Study 19049295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium ophthalmic solution 0.1%
Number of subjects: 54
Study 15258610 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy (DS)
Number of subjects: 13
Study 15258610 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 13
Study 12391104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (inspired O(2) fraction = 0.10) during Wingate test
Number of subjects: 10
Study 12391104 — intervention group
Group type: COMPARATOR
Intervention: Normoxia during Wingate test
Number of subjects: 10
Study 12391104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia during Wingate test
Number of subjects: 10
Study 10684957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led care (NLIU)
Number of subjects: 177
Study 10684957 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 177
Study 8869534 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional program
Number of subjects: 39
Study 8869534 — intervention group
Group type: COMPARATOR
Intervention: Scripted lecture with black-and-white transparencies
Number of subjects: 39
Study 1347278 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate, 600 mg three times daily (n = 19)
Number of subjects: 59
Study 1347278 — intervention group
Group type: COMPARATOR
Intervention: ranitidine, 300 mg at night (n = 20)
Number of subjects: 59
Study 1347278 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate plus ranitidine (n = 20)
Number of subjects: 59
Study 3157881 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone
Number of subjects: 21
Study 3157881 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg naloxone
Number of subjects: 21
Study 3157881 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 21
Study 31368249 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity intervention 3 days/week (120 min contact per week)
Number of subjects: 243
Study 31368249 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity intervention 5 days/week (200 min contact per week)
Number of subjects: 243
Study 31368249 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 days/week)
Number of subjects: 243
Study 31368249 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity intervention 1 day/week (40 min contact per week)
Number of subjects: 243